Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma
帕博西尼治疗晚期高分化/去分化脂肪肉瘤患者的开放标签 II 期试验的总生存期
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2026.106899
Babatunde, O O; Seier, K; Schwartz, G; Keohan, M L; D'Angelo, S P; Gounder, M M; Chi, P; Antonescu, C R; Landa, J; Qin, L-X; Crago, A M; Singer, S; Koff, A; Tap, W D; Dickson, M A
